Serum VEGFR-3 and survival of advanced gastric cancer patients treated with FOLFOX

doi:10.3748/wjg.v16.i17.2163

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 17

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3501)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

361

HTML

2707

Figures (1-2)

216

Tables (1-3)

217

Sum=3501

May 7, 2010 (publication date) through Nov 12, 2024

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. May 7, 2010; 16(17): 2163-2169
Published online May 7, 2010. doi: 10.3748/wjg.v16.i17.2163

Table 2 Serum VEGFR-3 and CEA levels and survival in advanced gastric cancer patients

Factors	n	MST (mo) (95% CI)	P¹
VEGFR-3 (ng/mL)
Low ≤ 70.6	52	15.400 (11.799-19.001)	< 0.001
High > 70.6	29	7.700 (5.691-9.709)
CEA (ng/mL)
Low ≤ 23.5	57	15.800 (11.223-20.377)	< 0.001
High > 23.5	24	8.600 (7.219-9.981)

¹Adjusted P-value based on log-rank statistics after 1000 bootstrap simulations. VEGFR-3: Vascular endothelial growth factor receptor-3; CEA: Carcinoembryonic antigen; CI: Confidence interval.

Citation: Ni XF, Wu CP, Jiang JT. Serum VEGFR-3 and survival of advanced gastric cancer patients treated with FOLFOX. World J Gastroenterol 2010; 16(17): 2163-2169
URL: https://www.wjgnet.com/1007-9327/full/v16/i17/2163.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i17.2163